A citation-based method for searching scientific literature

Jongmin Sim, Takuya Takayama, Junhun Cho, Seok Jin Kim, Won Seog Kim, Howe J Ree, Young Hyeh Ko. Medicine (Baltimore) 2019
Times Cited: 5







List of co-cited articles
6 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Comparison of the Lymph2Cx Assay and Hans Algorithm in Determining the Cell-of-Origin of Diffuse Large B-Cell Lymphomas, Not Otherwise Specified.
Inju Cho, Nara Yoon, Jiyeon Hyeon, Jongmin Sim, Hae Yong Yoo, Seok Jin Kim, Won Seog Kim, Young Hyeh Ko. Appl Immunohistochem Mol Morphol 2020
5
40

The 2016 revision of the World Health Organization classification of lymphoid neoplasms.
Steven H Swerdlow, Elias Campo, Stefano A Pileri, Nancy Lee Harris, Harald Stein, Reiner Siebert, Ranjana Advani, Michele Ghielmini, Gilles A Salles, Andrew D Zelenetz,[...]. Blood 2016
40

Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project.
Anamarija M Perry, Jacques Diebold, Bharat N Nathwani, Kenneth A MacLennan, Hans K Müller-Hermelink, Martin Bast, Eugene Boilesen, James O Armitage, Dennis D Weisenburger. Haematologica 2016
85
40

Subtype distribution of lymphomas in Southwest China: analysis of 6,382 cases using WHO classification in a single institution.
Qun-Pei Yang, Wen-Yan Zhang, Jian-Bo Yu, Sha Zhao, Huan Xu, Wei-Ya Wang, Cheng-Feng Bi, Zhuo Zuo, Xiao-Qing Wang, Juan Huang,[...]. Diagn Pathol 2011
155
40

Non-Hodgkin lymphoma in South East Asia: An analysis of the histopathology, clinical features, and survival from Thailand.
Tanin Intragumtornchai, Udomsak Bunworasate, Kitsada Wudhikarn, Arnuparp Lekhakula, Jakrawadi Julamanee, Kanchana Chansung, Chittima Sirijerachai, Lalita Norasetthada, Weerasak Nawarawong, Archrob Khuhapinant,[...]. Hematol Oncol 2018
16
40

Epidemiology and etiology of non-hodgkin lymphoma.
Brian C-H Chiu, Ningqi Hou. Cancer Treat Res 2015
59
40

Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy.
Chulin Sha, Sharon Barrans, Francesco Cucco, Michael A Bentley, Matthew A Care, Thomas Cummin, Hannah Kennedy, Joe S Thompson, Rahman Uddin, Lisa Worrillow,[...]. J Clin Oncol 2019
112
20


MYC rearrangement and MYC/BCL2 double expression but not cell-of-origin predict prognosis in R-CHOP treated diffuse large B-cell lymphoma.
Jie Xu, Jing-Lan Liu, L Jeffrey Medeiros, Wenting Huang, Joseph D Khoury, Timothy J McDonnell, Guilin Tang, Ellen Schlette, C Cameron Yin, Carlos E Bueso-Ramos,[...]. Eur J Haematol 2020
10
20

Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
Daisuke Ennishi, Aixiang Jiang, Merrill Boyle, Brett Collinge, Bruno M Grande, Susana Ben-Neriah, Christopher Rushton, Jeffrey Tang, Nicole Thomas, Graham W Slack,[...]. J Clin Oncol 2019
163
20

Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Tina Marie Green, Ken H Young, Carlo Visco, Zijun Y Xu-Monette, Attilio Orazi, Ronald S Go, Ole Nielsen, Ole V Gadeberg, Torben Mourits-Andersen, Mikael Frederiksen,[...]. J Clin Oncol 2012
484
20

Double-hit B-cell lymphomas.
Sietse M Aukema, Reiner Siebert, Ed Schuuring, Gustaaf W van Imhoff, Hanneke C Kluin-Nelemans, Evert-Jan Boerma, Philip M Kluin. Blood 2011
474
20

MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified.
Li-Xu Yan, Yan-Hui Liu, Dong-Lan Luo, Fen Zhang, Yu Cheng, Xin-Lan Luo, Jie Xu, Jie Cheng, Heng-Guo Zhuang. PLoS One 2014
33
20


Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.
Adam M Petrich, Mitul Gandhi, Borko Jovanovic, Jorge J Castillo, Saurabh Rajguru, David T Yang, Khushboo A Shah, Jeremy D Whyman, Frederick Lansigan, Francisco J Hernandez-Ilizaliturri,[...]. Blood 2014
305
20

Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.
Roland Schmitz, George W Wright, Da Wei Huang, Calvin A Johnson, James D Phelan, James Q Wang, Sandrine Roulland, Monica Kasbekar, Ryan M Young, Arthur L Shaffer,[...]. N Engl J Med 2018
931
20

Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.
Nathalie A Johnson, Kerry J Savage, Olga Ludkovski, Susana Ben-Neriah, Ryan Woods, Christian Steidl, Martin J S Dyer, Reiner Siebert, John Kuruvilla, Richard Klasa,[...]. Blood 2009
432
20

The cell-of-origin classification of diffuse large B cell lymphoma in a Korean population by the Lymph2Cx assay and its correlation with immunohistochemical algorithms.
Hee Sang Hwang, Dok Hyun Yoon, Jung Yong Hong, Chan-Sik Park, Yoon Se Lee, Young Hyeh Ko, Seok Jin Kim, Won Seog Kim, Cheolwon Suh, Jooryung Huh. Ann Hematol 2018
13
20

MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.
Heike Horn, Marita Ziepert, Claudia Becher, Thomas F E Barth, Heinz-Wolfram Bernd, Alfred C Feller, Wolfram Klapper, Michael Hummel, Harald Stein, Martin-Leo Hansmann,[...]. Blood 2013
388
20


Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.
Christine P Hans, Dennis D Weisenburger, Timothy C Greiner, Randy D Gascoyne, Jan Delabie, German Ott, H Konrad Müller-Hermelink, Elias Campo, Rita M Braziel, Elaine S Jaffe,[...]. Blood 2004
20

MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.
Anamarija M Perry, Yuridia Alvarado-Bernal, Javier A Laurini, Lynette M Smith, Graham W Slack, King L Tan, Laurie H Sehn, Kai Fu, Patricia Aoun, Timothy C Greiner,[...]. Br J Haematol 2014
131
20

Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab.
Paul N Meyer, Kai Fu, Timothy C Greiner, Lynette M Smith, Jan Delabie, Randy D Gascoyne, German Ott, Andreas Rosenwald, Rita M Braziel, Elias Campo,[...]. J Clin Oncol 2011
348
20

A high LDH to absolute lymphocyte count ratio in patients with DLBCL predicts for a poor intratumoral immune response and inferior survival.
Colm Keane, Joshua Tobin, Dipti Talaulikar, Michael Green, Pauline Crooks, Sanjiv Jain, Maher Gandhi. Oncotarget 2018
16
20

Variable global distribution of cell-of-origin from the ROBUST phase III study in diffuse large B-cell lymphoma.
Grzegorz S Nowakowski, Annalisa Chiappella, Thomas E Witzig, David W Scott, Michele Spina, Randy D Gascoyne, Lei Zhang, Jacqueline Russo, Janet Kang, Jingshan Zhang,[...]. Haematologica 2020
6
20

B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma: study of 39 cases.
Anamarija M Perry, David Crockett, Bhavana J Dave, Pamela Althof, Lisa Winkler, Lynette M Smith, Patricia Aoun, Wing C Chan, Kai Fu, Timothy C Greiner,[...]. Br J Haematol 2013
58
20

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications.
Elias Campo, Steven H Swerdlow, Nancy L Harris, Stefano Pileri, Harald Stein, Elaine S Jaffe. Blood 2011
20

High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology.
David W Scott, Rebecca L King, Annette M Staiger, Susana Ben-Neriah, Aixiang Jiang, Heike Horn, Anja Mottok, Pedro Farinha, Graham W Slack, Daisuke Ennishi,[...]. Blood 2018
116
20



B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
Matija Snuderl, Olga K Kolman, Yi-Bin Chen, Jessie J Hsu, Adam M Ackerman, Paola Dal Cin, Judith A Ferry, Nancy Lee Harris, Robert P Hasserjian, Lawrence R Zukerberg,[...]. Am J Surg Pathol 2010
252
20


Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Nathalie A Johnson, Graham W Slack, Kerry J Savage, Joseph M Connors, Susana Ben-Neriah, Sanja Rogic, David W Scott, King L Tan, Christian Steidl, Laurie H Sehn,[...]. J Clin Oncol 2012
664
20

Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies.
David W Scott, Anja Mottok, Daisuke Ennishi, George W Wright, Pedro Farinha, Susana Ben-Neriah, Robert Kridel, Garrett S Barry, Christoffer Hother, Pau Abrisqueta,[...]. J Clin Oncol 2015
249
20

Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Annette M Staiger, Marita Ziepert, Heike Horn, David W Scott, Thomas F E Barth, Heinz-Wolfram Bernd, Alfred C Feller, Wolfram Klapper, Monika Szczepanowski, Michael Hummel,[...]. J Clin Oncol 2017
143
20

Negative impact of concurrent overexpression of MYC and BCL2 in patients with advanced diffuse large B-cell lymphoma treated with dose-intensified immunochemotherapy.
Hiromichi Takahashi, Katsuhiro Miura, Masaru Nakagawa, Masahiko Sugitani, Yusuke Amano, Daisuke Kurita, Masashi Sakagami, Shimon Ohtake, Yoshihito Uchino, Hitomi Kodaira,[...]. Leuk Lymphoma 2016
12
20

The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement.
Steven Le Gouill, Pascaline Talmant, Cyrille Touzeau, Anne Moreau, Richard Garand, Nadine Juge-Morineau, Fanny Gaillard, Thomas Gastinne, Noël Milpied, Philippe Moreau,[...]. Haematologica 2007
165
20

Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas.
Clémentine Sarkozy, Alexandra Traverse-Glehen, Bertrand Coiffier. Lancet Oncol 2015
105
20

Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment.
Felicitas Hitz, J M Connors, R D Gascoyne, P Hoskins, A Moccia, K J Savage, L H Sehn, T Shenkier, D Villa, R Klasa. Ann Hematol 2015
54
20

Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412.
Grzegorz S Nowakowski, Fangxin Hong, David W Scott, William R Macon, Rebecca L King, Thomas M Habermann, Nina Wagner-Johnston, Carla Casulo, James L Wade, Gauri G Nagargoje,[...]. J Clin Oncol 2021
37
20

Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial.
Pier Luigi Zinzani, Cinzia Pellegrini, Letizia Gandolfi, Vittorio Stefoni, Federica Quirini, Enrico Derenzini, Alessandro Broccoli, Lisa Argnani, Stefano Pileri, Michele Baccarani. Clin Lymphoma Myeloma Leuk 2011
90
20

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.
Laurie H Sehn, Jane Donaldson, Mukesh Chhanabhai, Catherine Fitzgerald, Karamjit Gill, Richard Klasa, Nicol MacPherson, Susan O'Reilly, John J Spinelli, Judy Sutherland,[...]. J Clin Oncol 2005
757
20

Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).
Anita K Gandhi, Jian Kang, Courtney G Havens, Thomas Conklin, Yuhong Ning, Lei Wu, Takumi Ito, Hideki Ando, Michelle F Waldman, Anjan Thakurta,[...]. Br J Haematol 2014
380
20

Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.
Bruce D Cheson, Richard I Fisher, Sally F Barrington, Franco Cavalli, Lawrence H Schwartz, Emanuele Zucca, T Andrew Lister. J Clin Oncol 2014
20

Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL.
Andre Goy, Radhakrishnan Ramchandren, Nilanjan Ghosh, Javier Munoz, David S Morgan, Nam H Dang, Mark Knapp, Maria Delioukina, Edwin Kingsley, Jerry Ping,[...]. Blood 2019
75
20

ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma.
Grzegorz S Nowakowski, Annalisa Chiappella, Randy D Gascoyne, David W Scott, Qingyuan Zhang, Wojciech Jurczak, Muhit Özcan, Xiaonan Hong, Jun Zhu, Jie Jin,[...]. J Clin Oncol 2021
62
20

Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy.
Alan G Ramsay, Andrew J Clear, Gavin Kelly, Rewas Fatah, Janet Matthews, Finlay Macdougall, T Andrew Lister, Abigail M Lee, Maria Calaminici, John G Gribben. Blood 2009
189
20

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Christian Gisselbrecht, Bertram Glass, Nicolas Mounier, Devinder Singh Gill, David C Linch, Marek Trneny, Andre Bosly, Nicolas Ketterer, Ofer Shpilberg, Hans Hagberg,[...]. J Clin Oncol 2010
20

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.
A Lopez-Girona, D Mendy, T Ito, K Miller, A K Gandhi, J Kang, S Karasawa, G Carmel, P Jackson, M Abbasian,[...]. Leukemia 2012
521
20

A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma.
George Wright, Bruce Tan, Andreas Rosenwald, Elaine H Hurt, Adrian Wiestner, Louis M Staudt. Proc Natl Acad Sci U S A 2003
732
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.